Matthew A. Lunning, DO, FACP

Articles

CAR T-cells as Third-line and Beyond Therapy for FL

January 2nd 2024

Bijal Shah, MD, discusses recent data on CAR T-cell therapy as third-line and beyond treatment for FL.

Current Treatment Options in Second-line FL

January 2nd 2024

Experts on follicular lymphoma discuss second-line treatment options available for patients.

ASH 2023 Updates on Frontline Therapies in FL

January 2nd 2024

A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline FL.

Current Treatment Options in First-line FL

December 18th 2023

Experts on follicular lymphoma discuss first-line treatment options available for patients.

Practice Pearls for Physicians Considering CAR T-cell Therapy for Patients with LBCL

February 2nd 2023

Closing out this discussion of post-ASH 2022 perspectives, Matthew Lunning, DO, FACP, shares important clinical practice pearls for physicians considering CAR T-cell therapy for patients with LBCL.

Treatment Sequencing in LBCL: Clinical Trial and Real-World Data

February 2nd 2023

Experts discuss the role of clinical and real-world data in informing treatment sequencing in patients with large B-cell lymphoma (LBCL) in the academic and community setting,

Additional Key Data Updates from ASH 2022 on Treatment of LBCL

February 2nd 2023

Experts highlight additional data updates from the ASH 2022 annual meeting regarding the treatment of patients with LBCL.

Choosing the Appropriate CAR T-Cell Therapy in Patients with R/R DLBCL

February 2nd 2023

Dr Lunning, DO, FACP, shares his impressions on the toxicity profile of axi-cel and liso-cel, and how he approaches treatment decision making for patients with relapsed-refractory (R/R) large B-cell lymphoma (LBCL).

CAR T-Cell Therapy as Second-Line Treatment in LBCL

February 2nd 2023

Matthew Lunning, DO, FACP, discusses the role of CAR T-cell therapy in the second-line treatment of large B-cell lymphoma (LBCL).

Treatment Strategies for Patients with R/R LBCL

January 24th 2023

Experts provide their perspective on the treatment landscape for patients with relapsed-refractory (R/R) large B-cell lymphoma (LBCL).

CAR T-Cell Therapy in R/R LBCL: TRANSFORM, ZUMA-7, and PILOT Studies

January 24th 2023

In the context of CAR T-cell therapy, Manali Kamdar, MD, reviews TRANSFORM, ZUMA-7, and PILOT trials in the treatment of patients with relapsed-refractory (R/R) large B-cell lymphoma (LBCL).

Overview of Large B-Cell Lymphoma (LBCL)

January 24th 2023

Experts discuss Large B-Cell Lymphoma (LBCL) and treatment strategies for patients with LBCL.

Dr. Lunning on the Evolution of BTK Inhibitors in CLL

August 24th 2022

Matthew A. Lunning, DO, FACP, discusses the evolution of BTK inhibitors in chronic lymphocytic leukemia.

Role of Bispecifics and Future Promising Treatments in DLBCL

August 11th 2022

Shared excitement for bispecific antibodies and other promising novel therapies in the treatment of patients with DLBCL.

The Future of DLBCL Treatment

August 11th 2022

A look at exciting investigational agents and clinical trials for patients with relapsed/refractory diffuse large B-cell lymphoma.

Management and Work-up of Patients for Salvage Therapy

August 8th 2022

The panelists share their approach to the treatment and work-up of patients who require salvage therapy.

Strategies for Supportive Care and Monitoring in Patients Who Have Received CAR T-Cell Therapy

August 8th 2022

Experts in lymphoma take part in a discussion on supportive care for patients who receive CAR T-cell therapy.

A Closer Look at CAR T-Cell Therapy Clinical Trial Design

July 28th 2022

Subject matter experts in lymphoma reflect on chimeric antigen receptor T-cell therapy clinical trial design.

Clinical Trials Evaluating CAR T-Cell Therapies in Second-Line Treatment of Patients With DLBCL

July 28th 2022

Frederick Locke, MD, provides an in-depth look at data from 3 clinical trials investigating chimeric antigen receptor T-cell therapy in the second-line treatment of diffuse large B-cell lymphoma.

Therapeutic Sequencing and Bridging in DLBCL

July 22nd 2022

Optimizing approaches to therapeutic sequencing in relapsed/refractory DLBCL.